Immunotherapy improves outcomes of advanced endometrial cancer

Questions To Ask Your Health Care Provider

• Is my endometrial cancer considered advanced?
• Have you tested my cancer for biomarkers that may help guide treatment?
  • If so, what were my results?
  • If not, are there any tests that might be helpful for me?
• Is Keytruda plus chemotherapy an option for me?

Open Clinical Trials

The following studies are enrolling people with advanced endometrial cancer.  

• NCT04486352: A Study of Targeted Therapies for Patients With Recurrent Endometrial CancerA Study of Targeted Therapies for Patients With Recurrent Endometrial Cancer. This study will test the safety and effectiveness of different kinds of targeted therapy with or without atezolizumab in people with recurrent endometrial cancer. 
• NCT03607890: Nivolumab and Relatlimab in Advanced MSI-H Cancers Resistant to Prior PD-(L)1 Inhibitor. This study will evaluate the safety, effectiveness, and tolerability of the immunotherapy drugs nivolumab and relatlimab in patients with microsatellite instability-high (MSI-H) solid tumors resistant to prior PD-(L)1 therapy.
• NCT03955978: Dostarlimab in Addition to Standard of Care Definitive Radiation for Inoperable Endometrial Cancer. The purpose of this study is to evaluate dostarlimab compared to standard-of-care radiation therapy for patients with inoperable endometrial cancer to establish the safety and efficacy of inducing an anti-tumor immune response.
• NCT04463771: Safety and Efficacy of Retifanlimab (INCMGA00012) Alone or in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-based Chemotherapy. (POD1UM-204). This is a Phase 2 study of the PD-1 antibody retifanlimab in participants who have advanced or metastatic endometrial cancer that has progressed on or after platinum-based chemotherapy.

A number of other clinical trials for patients with endometrial cancer can be found here.